Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma

Abstract

EGFR-tyrosine kinase inhibitor (TKI) is an effective treatment for ASC. The frequency of EGFR mutation and clinical characteristics of the EGFR mutants in ASC are similar to those of Asian patients with adenocarcinoma.